DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: a case report.

Author(s): Gidwani P, Ramesh KH, Liu Y, Kolb EA

Affiliation(s): Department of Pediatric Hematology/Oncology, Children's Hospital at Montefiore, Montefiore Medical Center, Bronx, NY 10467, USA. pooja_gidwani@yahoo.com

Publication date & source: 2008, Chemotherapy., 54(2):120-4. Epub 2008 Feb 26.

Publication type: Case Reports

BACKGROUND: Despite significant advances in treatment and survival rates in pediatric acute leukemias, relapse remains a common reason for treatment failure. Survival following relapse is dismal for most patients. Clofarabine, a purine nucleoside analog, has recently been approved for use in relapsed and refractory pediatric acute lymphoblastic leukemia. Clofarabine and cytarabine together may be synergistic and have been used safely in adult leukemia patients. CASE REPORT: We describe the administration of this combination to a 9-year-old boy with multiple relapsed T-cell acute lymphoblastic leukemia who failed to achieve remission after the third attempt. He achieved complete morphologic and cytogenetic remission with 1 cycle of this combination. CONCLUSION: This case is the first report of successful remission induction in a multiple relapsed pediatric leukemia patient using the clofarabine and cytarabine combination. Although it is a single case, it highlights the need for further studies to assess safety and efficacy of this combination in pediatric patients.

Page last updated: 2008-06-22

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017